Free Trial
NASDAQ:TARS

Tarsus Pharmaceuticals (TARS) Stock Price, News & Analysis

Tarsus Pharmaceuticals logo
$46.47 -0.63 (-1.34%)
Closing price 04:00 PM Eastern
Extended Trading
$46.48 +0.01 (+0.02%)
As of 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Tarsus Pharmaceuticals Stock (NASDAQ:TARS)

Key Stats

Today's Range
$45.22
$48.96
50-Day Range
$41.29
$56.94
52-Week Range
$20.08
$57.28
Volume
1.09 million shs
Average Volume
640,294 shs
Market Capitalization
$1.78 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$63.67
Consensus Rating
Buy

Company Overview

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Remove Ads

Tarsus Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
50th Percentile Overall Score

TARS MarketRank™: 

Tarsus Pharmaceuticals scored higher than 50% of companies evaluated by MarketBeat, and ranked 578th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Tarsus Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Tarsus Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Tarsus Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Tarsus Pharmaceuticals are expected to grow in the coming year, from ($3.17) to ($1.44) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Tarsus Pharmaceuticals is -12.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Tarsus Pharmaceuticals is -12.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Tarsus Pharmaceuticals has a P/B Ratio of 7.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Tarsus Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    20.93% of the float of Tarsus Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Tarsus Pharmaceuticals has a short interest ratio ("days to cover") of 12.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Tarsus Pharmaceuticals has recently increased by 3.67%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Tarsus Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Tarsus Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    20.93% of the float of Tarsus Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Tarsus Pharmaceuticals has a short interest ratio ("days to cover") of 12.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Tarsus Pharmaceuticals has recently increased by 3.67%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Tarsus Pharmaceuticals has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 18 news articles for Tarsus Pharmaceuticals this week, compared to 4 articles on an average week.
  • Search Interest

    Only 1 people have searched for TARS on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Tarsus Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 8.25% of the stock of Tarsus Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    90.01% of the stock of Tarsus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Tarsus Pharmaceuticals' insider trading history.
Receive TARS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tarsus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

TARS Stock News Headlines

Tarsus prices $125M stock offering
Tarsus Pharmaceuticals announces $100M common stock offering
Has Trump finally met his match?
Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance to walk away with gains as high as 235%, 459%, and 700% - all while the stock market got cut in half. Could he be right again?
Tarsus Announces Proposed $100.0 Million Public Offering
Tarsus Pharma: Strong Execution In Xdemvy Commercialization
Pacira Pharmaceuticals (PCRX) Receives a Hold from Barclays
See More Headlines

TARS Stock Analysis - Frequently Asked Questions

Tarsus Pharmaceuticals' stock was trading at $55.37 at the beginning of the year. Since then, TARS stock has decreased by 16.1% and is now trading at $46.47.
View the best growth stocks for 2025 here
.

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) posted its earnings results on Tuesday, February, 25th. The company reported ($0.60) EPS for the quarter, topping analysts' consensus estimates of ($0.68) by $0.08. The company had revenue of $66.41 million for the quarter, compared to the consensus estimate of $58.80 million. Tarsus Pharmaceuticals had a negative trailing twelve-month return on equity of 55.86% and a negative net margin of 103.64%.

Tarsus Pharmaceuticals (TARS) raised $80 million in an initial public offering (IPO) on Friday, October 16th 2020. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. BofA Securities, Jefferies and Raymond James served as the underwriters for the IPO and LifeSci Capital and Ladenburg Thalmann were co-managers.

Tarsus Pharmaceuticals' top institutional investors include RTW Investments LP (8.47%), Paradigm Biocapital Advisors LP (6.62%), Jennison Associates LLC (6.54%) and Vanguard Group Inc. (5.53%). Insiders that own company stock include Vivo Capital Ix, Llc, Michael Ackermann, Seshadri Neervannan, Aziz Mottiwala, Bryan Wahl, Leonard M Greenstein, Dianne C Whitfield, Bobak R Azamian, Elizabeth Yeu Lin, Mark J Holdbrook, Andrew D Goldberg and Jose M Trevejo.
View institutional ownership trends
.

Shares of TARS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Tarsus Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET).

Company Calendar

Last Earnings
2/25/2025
Today
3/13/2025
Next Earnings (Estimated)
5/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TARS
Fax
N/A
Employees
50
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$63.67
High Stock Price Target
$78.00
Low Stock Price Target
$41.00
Potential Upside/Downside
+35.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-135,890,000.00
Net Margins
-103.64%
Pretax Margin
-103.64%

Debt

Sales & Book Value

Annual Sales
$182.95 million
Price / Cash Flow
N/A
Book Value
$5.95 per share
Price / Book
7.92

Miscellaneous

Free Float
35,073,000
Market Cap
$1.81 billion
Optionable
Optionable
Beta
1.05
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:TARS) was last updated on 3/13/2025 by MarketBeat.com Staff
From Our Partners